跳到正文
原文
BioPharma Dive· Delilah Alvarado·· 4 天前AI 评分53

强生以22亿美元收购Ollin Biosciences,获取在研眼病药物OLN324

J&J bets $2.2B on Ollin’s vision loss drug

AI 导读

强生宣布以22亿美元现金收购生物技术公司Ollin Biosciences,并获得其管线药物OLN324的开发权,后续最高另有11亿美元里程碑付款。Blackstone Life Sciences为OLN324的III期临床出资7.5亿美元。

正文

An article from site logo

Dive Brief

The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.

Published Nov. 16, 2026

Delilah Alvarado's headshot

Johnson & Johnson's pharmaceutical office in Madrid, Spain.

Johnson & Johnson's pharmaceutical office in Madrid, Spain. The company is investing $2 billion to expand its manufacturing capacity at Fujifilm Biotechnologies' facility in Holly Springs, North Carolina. Getty Images

Dive Brief:

  • Johnson & Johnson is betting up to around $3.3 billion on an eye drug that could eventually compete with blockbuster therapies like Roche’s Vabysmo. 
  • J&J said Monday it will acquire the developer of that medicine, biotechnology startup Ollin Biosciences, for $2.2 billion upfront and another $1.1 billion in milestones. Blackstone Life Sciences is putting up $750 million to support Phase 3 testing of that therapy, OLN324, in wet age-related macular degeneration and diabetic macular edema.   
  • The acquisition boosts an ophthalmology business that, so far, is largely built around contact lenses, medical devices and surgical equipment. J&J has only dabbled in prescription medicines for ophthalmic conditions, such as through a partnership with gene therapy developer MeiraGTx. 

Dive Insight:

Backed by Arch Venture Partners and TCGX, among others, Ollin launched last year with a pair of medicines licensed from China-based drug developers. Both drugs were designed to go after well-known targets and, in theory, offer certain advantages over established treatments. 

The drug at the heart of Monday’s deal, OLN324, originated at Shanghai-based Innovent Biologics. Like Roche’s Vabysmo, the drug targets the proteins VEGF and Ang2, both of which help drive the progression of age-related macular degeneration. Ollin, however, has claimed the drug may be more potent and have longer-lasting effects.

The payoff for success could be significant. Vabysmo has become a blockbuster treatment since its initial approval in 2022, and helped steal away market share from Regeneron Pharmaceuticals’ widely used medication Eylea. 

The deal also represents a “logical strategic fit” for J&J, given the company’s established presence in eye care, wrote RBC Capital Markets analyst Trung Huynh.

Still, though data from a Phase 1b study supported the drug’s potential, it’s unclear how “differentiated” OLN324 is in what has become a “very competitive and crowded space,” Huynh argued. The price J&J paid “appears high” when compared to the values of other competitors in the space, he added. 

Phase 3 studies posted on a federal clinical trial database indicate the company is running two studies in wet AMD and two in diabetic macular edema, all of which compare OLN324 to either Lucentis or Eylea. 

“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control,” said Kip Connor, J&J’s Ophthalmology Disease Area Stronghold Leader, in a statement. “The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients.”

The financing deal makes Blackstone eligible for certain milestone payments and royalties should OLN324 make it to market. 

Ollin’s other therapy, meanwhile, is a potential competitor to the thyroid eye disease drug Tepezza. That drug, OLN102, is currently in preclinical development. 

来源:BioPharma Dive · biopharmadive.com